Pancreatic Cancer Research

ResearcherGerman Cancer Research CenterActive in the last 2 years

Roland Michael Schmid

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0000-8976-3300; OpenAlex author ID A5101473723. Sources: OpenAlex.

Their work

Papers
57 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
190
Papers, trials and grants by year

2011: 6 papers · 2012: 2 papers · 2013: 3 papers · 2014: 2 papers · 2015: 2 papers · 2016: 3 papers · 2017: 3 papers · 2018: 2 papers · 2019: 3 papers · 2020: 6 papers · 2021: 6 papers · 2022: 3 papers · 2023: 2 papers · 2024: 3 papers · 2025: 7 papers · 2026: 4 papers

Papers 50 of 57

  1. The Protein Phosphatase Inhibitor LB100 Targets the Mesenchymal Lineage of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1002/mco2.70794↗
  2. Author Correction: Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarc… Co-author DOI 10.1038/s41591-026-04234-8↗
  3. Correction: Mitochondrial superoxide dismutase controls metabolic plasticity in pancreatic cancer. Co-author DOI 10.1186/s12964-026-02750-1↗
  4. Modeling pancreatic cancer tumor stroma co-evolution in an in ovo model Co-author DOI 10.64898/2026.06.26.734719↗
  5. Sensory neurons drive pancreatic cancer progression through glutamatergic neuron-cancer pseudo-synapses. Co-author DOI 10.1016/j.ccell.2025.09.003↗
  6. Development of a translational radiobiology platform using pancreatic cancer patient-derived organoids for personalized radiation oncology. Co-author DOI 10.1016/j.tranon.2025.102535↗
  7. A decision point between transdifferentiation and programmed cell death priming controls KRAS-dependent pancreatic cancer development. Co-author DOI 10.1038/s41467-025-56493-7↗
  8. Heterogeneity-driven phenotypic plasticity and treatment response in branched-organoid models of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41551-024-01273-9↗
  9. Label-free single-cell phenotyping to determine tumor cell heterogeneity in pancreatic cancer in real time. Co-author DOI 10.1172/jci.insight.169105↗
  10. c-Rel drives pancreatic cancer metastasis through fibronectin-integrin signaling-induced isolation stress resistance and EMT. Co-author DOI 10.1186/s12943-025-02486-5↗
  11. Mitochondrial superoxide dismutase controls metabolic plasticity in pancreatic cancer. Co-author DOI 10.1186/s12964-025-02555-8↗
  12. Identification of the unfolded protein response pathway as target for radiosensitization in pancreatic cancer. Co-author DOI 10.1016/j.radonc.2023.110059↗
  13. Author Correction: Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarc… Co-author DOI 10.1038/s41591-024-03054-y↗
  14. Comparison of endoscopic ultrasound-guided fine-needle aspiration and fine-needle biopsy to generate pancreatic cancer organoids: Randomized trial. Co-author DOI 10.1055/a-2257-3171↗
  15. Ras-dependent activation of BMAL2 regulates hypoxic metabolism in pancreatic cancer Co-author DOI 10.1101/2023.03.19.533333↗
  16. Phenotype screens of murine pancreatic cancer identify a Tgf-α-Ccl2-paxillin axis driving human-like neural invasion. Co-author DOI 10.1172/jci166333↗
  17. HDAC2 Facilitates Pancreatic Cancer Metastasis. Co-author DOI 10.1158/0008-5472.can-20-3209↗
  18. Epigenetic drug screening defines a PRMT5 inhibitor-sensitive pancreatic cancer subtype. Co-author DOI 10.1172/jci.insight.151353↗
  19. Identification of treatment-induced vulnerabilities in pancreatic cancer patients using functional model systems. Co-author DOI 10.15252/emmm.202114876↗
  20. Impact of DNA repair and reactive oxygen species levels on radioresistance in pancreatic cancer. Co-author DOI 10.1016/j.radonc.2021.03.038↗
  21. Mesenchymal Plasticity Regulated by Prrx1 Drives Aggressive Pancreatic Cancer Biology. Co-author DOI 10.1053/j.gastro.2020.09.010↗
  22. Bcl3 Couples Cancer Stem Cell Enrichment With Pancreatic Cancer Molecular Subtypes. Co-author DOI 10.1053/j.gastro.2021.03.051↗
  23. New Insights Into Pancreatic Cancer: Notes from a Virtual Meeting. Co-author DOI 10.1053/j.gastro.2021.04.082↗
  24. PALLD mutation in a European family conveys a stromal predisposition for familial pancreatic cancer. Co-author DOI 10.1172/jci.insight.141532↗
  25. [18F]FDG PET/MRI enables early chemotherapy response prediction in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13550-021-00808-4↗
  26. Unraveling ERBB network dynamics upon betacellulin signaling in pancreatic ductal adenocarcinoma in mice. Co-author DOI 10.1002/1878-0261.12699↗
  27. Radiosensitization by Kinase Inhibition Revealed by Phosphoproteomic Analysis of Pancreatic Cancer Cells. Co-author DOI 10.1074/mcp.ra120.002046↗
  28. Loss of Wasl improves pancreatic cancer outcome. Co-author DOI 10.1172/jci.insight.127275↗
  29. Implementing cell-free DNA of pancreatic cancer patient-derived organoids for personalized oncology. Co-author DOI 10.1172/jci.insight.137809↗
  30. Image-Based Molecular Phenotyping of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/jcm9030724↗
  31. Multiparametric Modelling of Survival in Pancreatic Ductal Adenocarcinoma Using Clinical, Histomorphological, Genetic and Image-Derived Parameters. Co-author DOI 10.3390/jcm9051250↗
  32. Evolving Treatment Paradigms for Pancreatic Cancer. First author DOI 10.1159/000503797↗
  33. A machine learning model for the prediction of survival and tumor subtype in pancreatic ductal adenocarcinoma from preoperative diffusion-weighted imaging. Co-author DOI 10.1186/s41747-019-0119-0↗
  34. A machine learning algorithm predicts molecular subtypes in pancreatic ductal adenocarcinoma with differential response to gemcitabine-based versus FOLFIRINOX … Co-author DOI 10.1371/journal.pone.0218642↗
  35. MTOR inhibitor-based combination therapies for pancreatic cancer. Co-author DOI 10.1038/bjc.2017.421↗
  36. Evolutionary routes and KRAS dosage define pancreatic cancer phenotypes. Co-author DOI 10.1038/nature25459↗
  37. The TALE homeodomain transcription factor MEIS1 activates the pro-metastatic melanoma cell adhesion molecule Mcam to promote migration of pancreatic cancer cel… Co-author DOI 10.1002/mc.22547↗
  38. HDAC1 and HDAC2 integrate the expression of p53 mutants in pancreatic cancer. Co-author DOI 10.1038/onc.2016.344↗
  39. Co-clinical Assessment of Tumor Cellularity in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-15-2432↗
  40. Hes1 Controls Exocrine Cell Plasticity and Restricts Development of Pancreatic Ductal Adenocarcinoma in a Mouse Model. Co-author DOI 10.1016/j.ajpath.2016.07.025↗
  41. Modeling Therapy Response and Spatial Tissue Distribution of Erlotinib in Pancreatic Cancer. Co-author DOI 10.1158/1535-7163.mct-15-0165↗
  42. Membranous CD24 drives the epithelial phenotype of pancreatic cancer. Co-author DOI 10.18632/oncotarget.9402↗
  43. A conditional piggyBac transposition system for genetic screening in mice identifies oncogenic networks in pancreatic cancer. Co-author DOI 10.1038/ng.3164↗
  44. Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/nm.3952↗
  45. A next-generation dual-recombinase system for time- and host-specific targeting of pancreatic cancer. Co-author DOI 10.1038/nm.3646↗
  46. Multimodal molecular imaging of integrin αvβ3 for in vivo detection of pancreatic cancer. Co-author DOI 10.2967/jnumed.113.129619↗
  47. Mdm2 inhibitors synergize with topoisomerase II inhibitors to induce p53-independent pancreatic cancer cell death. Co-author DOI 10.1002/ijc.27916↗
  48. [S3-guideline exocrine pancreatic cancer]. Co-author DOI 10.1055/s-0033-1356220↗
  49. Efemp1 and p27(Kip1) modulate responsiveness of pancreatic cancer cells towards a dual PI3K/mTOR inhibitor in preclinical models. Co-author DOI 10.18632/oncotarget.859↗
  50. Nuclear protein 1 promotes pancreatic cancer development and protects cells from stress by inhibiting apoptosis. Co-author DOI 10.1172/jci60144↗

Closest collaborators

The 25 strongest of 190 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Maximilian Reichert · 23 shared papers, 2013–2026 · strength 2.68
  2. Günter Schneider · 26 shared papers, 2011–2026 · strength 2.43
  3. Dieter Saur · 23 shared papers, 2011–2026 · strength 2.00
  4. Roland Rad · 18 shared papers, 2014–2026 · strength 1.98
  5. Rickmer Braren · 17 shared papers, 2014–2026 · strength 1.55
  6. Jens Thomas Siveke · 17 shared papers, 2011–2026 · strength 1.28
  7. Hana Algül · 14 shared papers, 2011–2025 · strength 1.26
  8. Wilko Weichert · 12 shared papers, 2018–2025 · strength 1.16
  9. İhsan Ekin Demir · 8 shared papers, 2021–2025 · strength 1.12
  10. Matthias Wirth · 12 shared papers, 2011–2026 · strength 1.09
  11. Felix Orben · 7 shared papers, 2020–2026 · strength 1.04
  12. H. Carlo Maurer · 7 shared papers, 2021–2026 · strength 1.03
  13. Alexander Muckenhuber · 9 shared papers, 2019–2025 · strength 0.91
  14. Henrik Einwächter · 4 shared papers, 2020–2026 · strength 0.91
  15. Sophie Dobiasch · 5 shared papers, 2020–2025 · strength 0.84
  16. Stephanie Elisabeth Combs · 5 shared papers, 2020–2025 · strength 0.84
  17. Marina Lesina · 9 shared papers, 2011–2025 · strength 0.83
  18. Irina Heid · 9 shared papers, 2011–2026 · strength 0.82
  19. Iréne Esposito · 11 shared papers, 2011–2026 · strength 0.78
  20. Christian Schneeweis · 5 shared papers, 2018–2026 · strength 0.76
  21. Georgios A. Kaissis · 7 shared papers, 2019–2025 · strength 0.69
  22. Alexander Herner · 6 shared papers, 2015–2026 · strength 0.68
  23. Sankaranarayanan Ramasubramanian · 2 shared papers, 2025–2026 · strength 0.66
  24. Stefanie Bärthel · 4 shared papers, 2023–2026 · strength 0.66
  25. Elisabeth Heßmann · 5 shared papers, 2015–2026 · strength 0.65

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.